Atea Pharmaceuticals (AVIR) Enterprise Value (2019 - 2026)

Atea Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$256.0 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 39.83% year-over-year to -$256.0 million; the TTM figure through Mar 2026 stood at -$256.0 million (up 39.83% YoY), while the FY2025 annual figure was -$301.8 million, up 64.11% from the prior year.
• Enterprise Value was -$256.0 million for Q1 2026 at Atea Pharmaceuticals, up from -$301.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$256.0 million in Q1 2026 to a low of -$859.3 million in Q3 2024.
• Historically, Enterprise Value has averaged -$576.0 million across 5 years, with a median of -$608.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 45.48% in 2024, then soared 64.11% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$646.7 million in 2022, then climbed by 10.61% to -$578.1 million in 2023, then sank by 45.48% to -$841.0 million in 2024, then soared by 64.11% to -$301.8 million in 2025, then rose by 15.18% to -$256.0 million in 2026.
• The last three Enterprise Value figures came in at -$256.0 million (Q1 2026), -$301.8 million (Q4 2025), and -$329.3 million (Q3 2025), per Business Quant data.